Loading stock data…
$30.21-0.61 (-1.98%)
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Agios Pharmaceuticals, Inc. in the Healthcare sector is trading at $30.21 with a market capitalization of $1.9B. Wall Street consensus targets $46.00 (8 analysts), implying a +52.3% move over the next 12 months. The stock is currently 34% below its 52-week high of $46.00, remaining 3.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $44.74M↑ | $20.75M↑ | $19.97M↑ | $12.88M↑ | $12.46M |
| Gross Profit | $41.75M↑ | $19.43M↑ | $18.09M↑ | $11.20M↑ | $10.75M |
| Operating Income | -$110.55M↓ | -$110.03M↑ | -$121.58M↓ | -$116.87M↑ | -$127.06M |
| Net Income | -$100.70M↓ | -$99.11M↑ | -$108.04M↓ | -$103.43M↑ | -$112.02M |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase ...